Free Trial
OTCMKTS:CRXTQ

Clarus Therapeutics (CRXTQ) Stock Price, News & Analysis

Clarus Therapeutics logo
$0.0010 0.00 (0.00%)
As of 03/6/2023

About Clarus Therapeutics Stock (OTCMKTS:CRXTQ)

Key Stats

Today's Range
$0.0010
$0.0010
50-Day Range
N/A
52-Week Range
$0.00
$3.94
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

Receive CRXTQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clarus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRXTQ Stock News Headlines

Real Americans Don’t Wait on Wall Street’s Next Move
What's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.
Clarus Therapeutics Holdings Inc.
Clarus Therapeutics Holdings, Inc. (CRXT)
See More Headlines

CRXTQ Stock Analysis - Frequently Asked Questions

Clarus Therapeutics' stock was trading at $0.0010 at the beginning of the year. Since then, CRXTQ stock has increased by 0.0% and is now trading at $0.0010.
View the best growth stocks for 2025 here
.

Clarus Therapeutics Holdings, Inc. (OTCMKTS:CRXTQ) issued its earnings results on Thursday, November, 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.55. The business had revenue of $4.29 million for the quarter, compared to the consensus estimate of $3.30 million.

Shares of CRXTQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/18/2021
Today
4/19/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:CRXTQ
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (OTCMKTS:CRXTQ) was last updated on 4/19/2025 by MarketBeat.com Staff
From Our Partners